LXRX Financial Facts
Interest expense: -1.65MCollaborative research: 27.69M
See Full Income Statement
Accounts receivable, net of allowances of $35: 738K
Total equity: 185.18M
See Full Balance Sheet
Lexicon Pharmaceuticals, Inc. (LXRX) Earnings
|
Expand Research on LXRX
Next EPS Date | 3/14/24 | EPS Growth Rate | N/A |
---|---|---|---|
Average EPS % Beat Rate | -12.7% | Revenue Growth Rate | N/A |
Average % Move 1-Wk after EPS | -8.6% | Normal Earnings Time | After Close |
Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
---|---|---|---|---|---|---|---|---|---|---|---|
3/14/24 | Q423 | N/A | -$0.21 | N/A | N/A | $5.04M | N/A | N/A | N/A | ||
11/2/23 | Q323 | N/A | -$0.21 | N/A | N/A | $2.06M | N/A | N/A | N/A | ||
11/8/23 | Q323 | -$0.21 | -$0.21 | $0.00 | $160K | $2.06M | N/A | ![]() | ![]() | Details | |
8/3/23 ![]() |
Q223 | -$0.22 | -$0.18 | -$0.04 | $320K | $133.33K | N/A | ![]() | ![]() | Details | |
5/4/23 | Q123 | N/A | -$0.19 | N/A | N/A | $50K | N/A | N/A | N/A | ||
3/1/23 | Q422 | N/A | -$0.13 | N/A | N/A | $50K | N/A | N/A | N/A | ||
11/9/22 | Q322 | -$0.16 | -$0.14 | -$0.02 | $23K | $100K | N/A | ![]() | ![]() | Details | |
11/9/22 | Q322 | -$0.16 | -$0.14 | -$0.02 | $23K | $100K | N/A | ![]() | ![]() | Details |